Subcutaneous Nivolumab for Gastric Cancer: Practice-Changing Potential?

Laurence Albiges, MD, PhD, of Institute Gustave Roussy, shares her thoughts on the FDA approval of subcutaneous nivolumab in gastric cancer, as well as how the approval figures to impact clinical practice.

She breaks down the convenience of this approval for both patients and clinicians alike.